Post on 15-May-2018
CURRICULUM VITAE
David L. DeRemer, Pharm.D, FCCP, BCOP November 2017
______________________________________________________________________________
GENERAL INFORMATION
Office Address: University of Florida College of Pharmacy
Department of Pharmacotherapy and Translational Research
HPNP 2302
Gainesville, FL 32610
Email: dderemer@cop.ufl.edu
Telephone: Office: 352-273-6225
Fax: 352-273-6485
Present Position: Clinical Associate Professor
Assistant Director of Experimental Therapeutics and Incubator (ETI)
University of Florida College of Pharmacy
University of Florida Health Cancer Center
EDUCATION
1992-1996 B.S., Biology
University of Kentucky College of Arts and Sciences
1998-2002 Doctor of Pharmacy
University of Kentucky College of Pharmacy
POSTDOCTORAL TRAINING
2002-2003 Pharmacy Practice Residency (ASHP-Accredited)
University of Kentucky Chandler Medical Center
Director: Kelly Smith Pharm.D., BCPS, FASHP, FCCP
2003-2004 Hematology-Oncology Residency (ASHP-Accredited)
University of Kentucky Chandler Medical Center
Director: Val Adams Pharm.D., FCCP, BCOP
2004-2005 Oncology Postdoctoral Fellowship
Drug Discovery/Development
University of Kentucky Chandler Medical Center
Director: Val Adams Pharm.D., FCCP, BCOP
David L. DeRemer - CV
2
ACADEMIC RANK AND APPOINTMENTS
9/2006-6/2012 Clinical Assistant Professor
University of Georgia College of Pharmacy
Department of Clinical and Administrative Pharmacy
Clinical and Experimental Therapeutics (CET) Program
Augusta, GA
7/2012- 8/2017 Clinical Associate Professor
University of Georgia College of Pharmacy
7/2013- 8/2017 Adjunct Clinical Associate Professor
Medical College of Georgia
Department of Medicine, Section of Hematology/Oncology
Augusta, GA
9/2017- present Clinical Associate Professor
University of Florida College of Pharmacy
Department of Pharmacotherapy and Translational Research
PROFESSIONAL LICENSURE AND BOARD CERTIFICATION
2002- current Kentucky Pharmacy Licensure (#012403)
2005- current Georgia Pharmacy Licensure (#022799)
2006- current Board of Pharmaceutical Specialties
Board Certified Oncology Pharmacist (#506006838)
Recertified by CE (2012)
PROFESSIONAL EXPERIENCE
1996-1998 Senior Lab Technician
University of Kentucky College of Medicine
Department of Microbiology & Immunology
Jesse Sisken, Ph.D. Laboratory
1999-2002 CVS Pharmacy Intern
Lexington, KY
2004-2005 Hematology/Oncology PRN Pharmacist
University of Kentucky Markey Cancer Center
Lexington, KY
David L. DeRemer - CV
3
2005-2006 Hematology/Oncology Clinical Specialist
Bone Marrow Transplant/Oncology Clinical Specialist
Medical College of Georgia (MCG Inc.)
Augusta, GA
2006- 2013 Inpatient Hematology/Oncology Clinical Specialist
Inpatient Bone Marrow Transplant/Oncology Clinical Specialist
Georgia Regents University Medical Center
(Formerly Georgia Health Sciences University and MCG Health)
Augusta, GA
2013- 2017 Outpatient BMT/Hematological Malignancies Clinical Specialist
Georgia Cancer Center
Augusta, GA
2017- present Assistant Director of the Experimental Therapeutics Incubator
University of Florida Health Cancer Center (UFHCC)
Gainesville, FL
TEACHING EXPERIENCE
University of Florida College of Pharmacy
Pharm.D. Curriculum
2018 PHA5784C Patient Care IV – 3 contact hours
Lecturer – Colorectal cancer screening
Active Learning – Colorectal Cancer
PHA5081C Complex Patients – 1 contact hour
Lecturer- Oncologic emergencies
University of Georgia College of Pharmacy
Pharm.D. Curriculum
2006-2007 PHRM 3800: Clinical Applications - 8 contact hours, patient based learning
Course Coordinator
Facilitator – Rheumatoid arthritis
Facilitator – Multiple myeloma
Facilitator - Hypothyroidism
Facilitator – Coronary Artery Disease
David L. DeRemer - CV
4
Facilitator – Breast cancer
Facilitator – Crohn’s disease
2007-2008 PHRM 5210: Clinical Oncology Elective – 12 contact hours, interactive cases, s
seminars, experiential component
Course Coordinator
2007-2017 PHRM 5870: Pharmacotherapy II – 6 contact hours, interactive cases, team-
based learning
Course coordinator (2017)
Lecturer – Breast cancer (1 semester)
Lecturer – Bone marrow transplantation (3 semesters)
Lecturer – Growth factors (1 semester)
Lecturer – CINV (6 semesters, co-mentored PGY2 resident)
Lecturer - Systemic fungal infections (5 semesters)
Lecturer – Oncologic emergencies (2 semesters)
2007-2008 PHRM 5140: Clinical Skills Lab – 12 contact hours, facilitated labs with OSCEs
Co-Coordinator
2009- 2012 PHRM 4190: Cancer and Chemotherapy - 10-12 contact hours
Co-Coordinator
Lecturer – Chemotherapy dosing, delivery, terminology
Lecturer – Adverse events of chemotherapy and palliation
Lecturer – Prostate cancer
Lecturer – NHL/Hodgkin lymphoma
Lecturer – Pediatric malignancies
Lecturer - Chronic leukemias
Lecturer – Acute leukemias
Lecturer – Colorectal cancer
Lecturer – Lung cancer and mesothelioma
Lecturer – Disease related symptoms
2010 -2011 PHRM 5210: Landmark Clinical Studies in Oncology and Clinical Applications
Seminars, interactive cases, experiential- Elective course
Co-coordinator
2011-2017 PHRM 5920: Clinical Seminar- 3-5 contact hours/semester – student mentoring
2013- 2015 PHRM 5190: Anticancer therapeutics – 5-10 contact hours, didactic
Lecturer – see above (PHRM 4190)
David L. DeRemer - CV
5
2015 PHRM 5210: Insights into Clinical Practice – 2 contact hours, small group
interactive cases
2015 PHRM 5210: Resident Rounds- 12 contact hours, small group, didactic lectures
Course coordinator
2016-2017 PHRM 3520: Interpreting Clinical Lab Tests – 1 contact hour, didactic
Lecturer – Hematology: Red and White Blood Cells
2016 PHRM 3030: Essentials of Pharmacy Practice I – 8 contact hours, small group
recitation
2017 PHRM 3040: Essentials of Pharmacy Practice II – 8 contact hours, small group
recitation
2017 PHRM 4040: Essentials of Pharmacy Practice IV – 2 contact hours, skills lab
Skills Lab – Handling hazardous agents
2017 PHRM 5210: Integrated Patient Cases – 2 contact hours, cases and simulated
EMR
Experiential Experiences
Year Rotations Practice Site (s) Students- hours
2007- 2017 5901-5908 (APPE)
Inpatient Hematology/Oncology
BMT
Outpatient Oncology
8-10 students per year 150- 200 contact hours per rotation
2012- 2017 IPPE Oncology 8-12 students per year
Resident Graduate Curriculum
Year Rotations Format Graduate students- hours
2011-2017 PHRM 7210 Advanced Pharmacy Care
Small group discussion 5-7 students- 5 contact hours/year
2011-2017 (Fall semesters)
PHRM 7810 Pharmacy Care
Direct precepting 1-2 students- > 100 contact hours
2011-2017 PHRM 7910 Adv Pharmacy Care
Direct precepting >100 contact hours
2011- 2017
PHRM 7830 Residency Research
Research advising 1-2 students- > 100 contact hours
2011- 2017 PHRM 7840 Teaching Pharmacy Practice
Advising 1 students -> 10 contact hours
David L. DeRemer - CV
6
2011- 2017 PHRM 7940 Teaching Pharmacy Practice PGY2
Advising 1-2 students -> 10 contact hours
2012-2013 PHRM 7210 Special Topics PGY2 Oncology Residents
Interactive cases 10 contact hours
Medical College of Georgia College of Allied Health- Physician Assistant Program
2009-2015 Chemotherapy 101
Chemotherapy Induced Nausea-Vomiting
Format: Didactic lectures
Medical College of Georgia College of Nursing
2008-2012 NSG 7430 - Pharmacology for Advanced Practice Nurses
Pain Management (3 contact hours annually)
Adjuvant Treatments in Cancer (3 contact hours annually)
University of Kentucky College of Pharmacy
Spring 2004 Integrated Applied Therapeutics II (PHR 963)
(2 contact hours)
Fall 2004 Integrated Applied Therapeutics I (PHR 962)
(2 contact hours)
Fall 2003 Contemporary Aspects of Pharmacy Practice (PHR 939)
(8 contact hours)
Spring 2002 Contemporary Aspects of Pharmacy Practice (PHR 919)
(8 contact hours)
University of Kentucky College of Allied Health Sciences-Physician Assistant
Spring 2003 Pharmacology Course
Immunomodulating Agents
Antineoplastic Agents
(2 contact hours)
POSTGRADUATE TRAINEES
David L. DeRemer - CV
7
PGY2 Oncology Pharmacy Residency Program Director
Year Graduate Resident First Clinical Position
2011-2012 Katerina Katsanevas Butler, Pharm.D BCOP
Oncology Clinical Specialist VA Medical Center Salt Lake City, UT
2012-2013 Stephen Clark, Pharm.D. BCOP BMT Clinical Specialist University of North Carolina
Chapel Hill, NC
2012-2013 Alison Steinbach, Pharm.D Outpatient Clinical Specialist West Penn Allegheny Hospital
Pittsburgh, PA
2013-2014 Megan Hartranft, Pharm.D. BCPS, BCOP
Clinical Assistant Professor Rosalind Franklin College of Pharmacy
Rush Cancer Center Chicago, IL
2014-2015 Sarah Evans, Pharm.D. BCOP Outpatient Clinical Specialist The Ohio State Medical Center
James Cancer Center Columbus, OH
2015- 2016 Julianne Orr, Pharm.D. Outpatient Clinical Specialist Indiana Health Indianapolis, IN
2016-2017 Ben Andrick, Pharm.D. BMT Clinical Specialist Geisinger Health System
Danville, PA
7/2017-8/2017 Morgan Gwynn, Pharm.D. PGY2 Resident at AU/UGA
UGA Clinical and Experimental Therapeutics (CET) Clinical Program Training
Year Graduate Student Rotation
2010 Belal Al-Husein, M.S. Inpatient Oncology
2012 Ahmed Al-Azayzih, Pharm.D. BCOP Inpatient Oncology
2014 Harika Sabbineni, B.Pharm. Outpatient BMT
UGA Clinical and Experimental Therapeutics Dissertation Committee Member
Year Graduate Student Thesis Title
2010-2011 Belal Al-Husein, M.S. Molecular mechanisms regulating simvastatin-mediated inhibition of prostate cancer cellular functions in vitro and tumor growth in vivo
David L. DeRemer - CV
8
2011-2012 Ahmed Al-Azayzih, Pharm.D. BCOP Role of Akt in myofibroblast differentiation leading to pulmonary vascular remodeling and idiopathic pulmonary fibrosis
2015-current Abdul M. Alwhaibi, Pharm.D. In-progress
PGY1 Pharmacy Residency Precepting
Year Graduate Resident Rotation
2010-2011 Katerina Katsanevas, Pharm.D BCOP
Inpatient hematology/oncology
2009-2010 Karly O’Brien, Pharm.D. Inpatient hematology/oncology
2009-2010 Ashley Richard, Pharm.D. Inpatient hematology/oncology
2009-2010 Amber Bradley, Pharm.D. BCOP Inpatient hematology/oncology
2008-2009 Neha Dosi, Pharm.D. Inpatient hematology/oncology
2008-2009 Evelina Maciuleviciute, Pharm.D.
Inpatient hematology/oncology
2007-2008 Tim Robinson, Pharm.D. BCPS Inpatient hematology/oncology
2007-2008 Kinjal Vikal, Pharm.D. Inpatient hematology/oncology
CERTIFICATIONS/OTHER TRAINING
2015 Chairs and Academic Administrators Management Program (CAAMP)
Academy for Academic Leadership
Atlanta, GA
2014 ACCP Focused Investigator Training (FIT) Program
Athens, GA
2012 CITI- Collaborative IRB Training Initiative Certification
Georgia Health Sciences University
Refresher Course Completed (2006, 2009)
2012 CITI Certification for Institutional Review Board Members
Georgia Health Sciences University
2007 Biosafety Training Certification
David L. DeRemer - CV
9
Medical College of Georgia
2006 Saf-T-Pak Inc Biological Specimens Certification
Recertification (2015- Safe Transports of Biological Substances)
Medical College of Georgia
2004 Scholarship of Teaching and Learning Certificate Program
University of Kentucky Chandler Medical Center
2003 Navigating the Clinical Research Process Investigator Training
University of Kentucky Chandler Medical Center
2003 Advanced Cardiac Life Support Certification
University of Kentucky Chandler Medical Center
2002 Adult Immunizations Certification
University of Kentucky College of Pharmacy
PRESENTATIONS
National
1. Schedule-dependent Synergism and Antagonism between Paclitaxel and Topotecan in Human
Ovarian Cancer Cell Lines in vitro. Scientific Paper Platform Presentation. Presented at American
College of Clinical Pharmacy (ACCP) Annual Meeting; San Francisco, CA. October 2005
2. Strategies for Success in Pharmacy Board Certification: A Panel Discussion. Panel – Smith KM,
Canada TW, Divine H, Jennings HR. Presented at the 42nd American Society of Health Systems
Pharmacists (ASHP) Midyear Clinical Meeting; Las Vegas, NV. December 2, 2007
3. Hodgkin Lymphoma BCOP Recertification Presentation. Presented at the 9th Annual Hematology
Oncology Pharmacists Association (HOPA) Annual Meeting; Los Angeles, CA. March 2013.
4. Trending now #ExcellenceInPrecepting – effective ways to incorporate social media into clinical
practice. Co-presenters- Clark S and Hartranft M. Presented at the ASHP National Pharmacy
Preceptors Conference; Washington DC. August 22, 2013.
5. Have you submitted that paper yet? Successfully precepting student and resident research
projects. Co-presenters- May JR, Phillips BJ, Phillips M. Presented at the ASHP National
Pharmacy Preceptors Conference; Washington DC. August 23, 2013.
6. Hodgkin Lymphoma BCOP Recertification Presentation. Presented at American College of
Clinical Pharmacy (ACCP) Annual Meeting Albuquerque, NM. October 15, 2013.
David L. DeRemer - CV
10
7. Hodgkin Lymphoma BCOP Recertification Presentation. Presented at ASHP Annual Meeting
Orlando, FL. December 10, 2013.
8. Evaluation of the effects of obesity on the epigenome in acute myeloid leukemia patients:
Correlation with clinical outcomes and drug response. The Great Eight Best Paper Presentations
Series. Presented at American College of Clinical Pharmacy (ACCP) Annual Meeting Austin, TX.
October 13, 2014
9. Hematology/Oncology PRN Focus Session: Confronting the Global Epidemic of Human
Papillomavirus (HPV) and Associated Malignancies. Moderator at Global American College of
Clinical Pharmacy (ACCP) Annual Meeting San Francisco, CA. October 19, 2015.
10. Recent Advances in the Treatment and Management of Lymphomas. Presented at HOPA BCOP
Updates Course Orlando, FL. July 16, 2016.
11. Malignancy in the HIV Patient. Presented at the ACCP Annual Meeting Hollywood, FL. October
24, 2016.
12. Oral Chemotherapy Education. Presented at the National Community Oncology Dispensing
Association (NCODA) Annual Summit Atlanta, GA. October 29, 2016.
13. Managing Acute Lymphoblastic Leukemia (ALL): A Review on Diagnosis and Clinical
Considerations for the Healthcare Professional. Webinar provided by Specialty Pharma
Education Center, 2016.
14. Cracking the Code on Oral Chemotherapy: Pharmacotherapy Management and Counseling
Strategies. Presented at the ACCP Annual Meeting Phoenix, AZ. October 10th, 2017.
15. Oral Chemotherapy Education. Presented at the NCODA Annual Meeting Orlando, FL. October
19, 2017.
16. Emerging Treatment Options for Relapsed/Refractory Hodgkin Lymphoma. ASHP Advantage
Webinar. October 26, 2017.
Regional
1. The Specific Role of 92kDa Type IV Collagenase in Metastatic Tumor Cells Howard Hughes
Research Award Winners Presentation. Kentucky/Tennessee Academy of Science Joint Meeting
Bowling Green, KY. May 1996
David L. DeRemer - CV
11
2. Erythropoietin Response in Patients Concurrently Receiving Capecitabine ACPE accredited
continuing education program. Southeastern Residency Conference University of Georgia.
Athens, GA. May 2003
3. Thymoquinone: Analytical Method and Assay Validation. Southeastern Residency Conference.
ACPE accredited continuing education program. University of Georgia. Athens, GA. May 2004
4. Selected Overview of Recently Approved Oncology Agents: Targeting New Molecular Targets
Kentucky Health System Pharmacists (KSHP) Annual Meeting. ACPE accredited continuing
education program.. Lexington, KY. September 2004.
5. New Oncology Agents. Georgia Health System Pharmacists (GHSP) Fall Annual Meeting
ACPE accredited continuing education program. Helen, GA October 2006.
6. The Generational Joust: Strategies for Boomers and GenXers as the Millennials Enter the
Profession of Pharmacy. Georgia Health System Pharmacists (GHSP) Summer Annual Meeting.
ACPE accredited continuing education program. Amelia Island, FL June 2008
7. Breast and Gynecological Cancers. South Carolina Pharmacists Association Summer Meeting
ACPE accredited continuing education program. Hilton Head, SC June 2010.
8. Managing Vascular Complications Associated with Novel Targeted Chemotherapy Agents
Georgia Health System Pharmacists (GHSP) Summer Annual Meeting. ACPE accredited
continuing education program. Amelia Island, FL July 2012.
9. Confronting the Rise of Cancers in the HIV Population. Georgia Health System Pharmacists
(GHSP) Summer Annual Meeting. ACPE accredited continuing education program. Amelia Island,
FL July 2017.
State
1. Angiogenesis: Switching On/Off Molecular Targets for Differing Clinical Outcomes ACPE
accredited continuing education program. MCG/UGA Pharmacy Grand Rounds, Augusta, GA.
February 2006.
2. What’s “Hot” in the Treatment of Leukemias. ACPE accredited continuing education program
MCG/UGA Pharmacy Grand Rounds, Augusta, GA. October 2006.
3. Perspective of a New Generation Xer Professor- Challenges and Strategies of Teaching the
Millennials. ACPE accredited continuing education program/ MCG/UGA Pharmacy Grand
Rounds, Augusta, GA. October 2007.
4. Neurotoxicity of Chemotherapeutic Agents. MCG Neurology Resident Ground Rounds Series
David L. DeRemer - CV
12
Medical College of Georgia, Augusta, GA. February 2008.
5. Recent Significant Advances in Oncology. ACPE accredited continuing education program.
MCG/UGA Pharmacy Grand Rounds, Augusta, GA. Transmitted video to Savannah and Athens,
GA. April 2009.
6. Making it less MUDdy: Understanding Matched Unrelated Donor Bone Marrow Transplants.
ACPE accredited continuing education program. GHSU/UGA Pharmacy Grand Rounds, Augusta,
GA. Transmitted video to Savannah, Athens, and Albany, GA. April 2011
7. Maintaining the Maintenance: Is this the Future of Cancer Therapy. ACPE accredited continuing
education program. GHSU/UGA Pharmacy Grand Rounds, Augusta, GA. Transmitted video to
Savannah, Athens, and Albany, GA. October 2012.
8. Recent Advances in Cancer Immunotherapy: Developing a Killer Instinct. ACPE accredited
continuing education program. GRU/UGA Pharmacy Grand Rounds, Augusta, GA. Transmitted
video to Savannah, Athens, and Albany, GA. September 2014.
9. Hematopoietic Growth Factors. Augusta University Division of Hematology/Oncology Fellows
Grand Rounds. February 8, 2017.
PEER-REVIEWED PUBLICATIONS
1. Sisken J, DeRemer DL. Power frequency electromagnetic fields and the capacitative calcium
entry system in SV40-transformed Swiss 3T3 cells. Radiation Research 2000;153:699.
2. Ustun C, Farrow S, El-Geneidy, DeRemer D, Jillella A. A serious complication of allogeneic
stem cell transplantation: Relapsing Pseudomonas aeruginosa panniculitis. Clinical Medicine:
Oncology 2007: I 91-94
3. Ustun C, Farrow S, DeRemer D, Fain H, Jillella A. Early fatal Rhizopus infection on voriconazole
prophylaxis following allogeneic stem cell transplantation. Bone Marrow Transplant 2007 Jun;
39(12):807-8.
4. Ustun C, DeRemer DL, Steele J, Forseen C, Fisher JF, Jillella AP. Fatal breakthrough
Aspergillus fumigatus and Candida glabrata infections in a leukemia patient on
posaconazole prophylaxis. Int J Antimicrob Agents. 2008 Oct; 32(4):365-6.
5. Ustun C, Kalla A, Farrow S, DeRemer DL, Jillella A. Decitabine as “bridge therapy” to
a MUD transplant in relapsed AML postautologous stem cell transplantation.
Am J Hematol. 2008 Oct; 83(10):825-7
David L. DeRemer - CV
13
6. DeRemer DL, Natarajan K, Ustun C. Nilotinib (Tasigna®): A second generation tyrosine
kinase inhibitor for the treatment of chronic myelogenous leukemia.
Clin Ther. 2008 Nov;30(11):1956-75.
7. Ustun C, DeRemer DL, Jillella A, Bhalla KN. Investigational drugs targeting FLT3 for leukemia.
Expert Opinion Investig Drugs 2009 Oct;18(10):1445-56.
8. Adams VR, DeRemer DL, Stevich B, Mattingly C, Gallt B, Subramanian T, Troutman HM,
Speilmann HP. Anticancer activity of novel unnatural synthetic isoprenoids. Anticancer Res.
2010 Jul;30(7):2505-12.
9. Lewis G, Hall P, Eisa N, DeRemer DL, Dobbins R, El-Geneidy M, Jillella A, Ustun C. Acute
myelogenous leukemia patients are at low risk for invasive fungal infections after high dose
cytarabine consolidations and thus do not require prophylaxis. Acta Haematologica 2010
Nov 12;124(4):206-213
10. Ustun C, Jillella A, Shah R, Sterling K, DeRemer DL, et al. Second allogeneic stem cell
transplantation from different donor improves severe steroid-resistant gut GVHD.
Bone Marrow Transplant 2010 Nov;45(11):1658-60
11. Willis LM, Somanath PR, El-Remessy AB, DeRemer DL, Fagan SC.
Angiotensin receptor blockers and angiogenesis: Clinical and experimental evidence.
Clin Science 2011 Apr; 120 (8):307-19
12. DeRemer DL, Katsanevas K, Ustun C. Critical appraisal of nilotinib in the front-line treatment of
chronic myeloid leukemia. Cancer Manag and Res. 2011 Mar 10:3:65-78.
13. Ustun C, DeRemer DL, Akin C. Tyrosine inhibitors in the treatment of systemic mastocytosis.
Leukemia Res. 2011 Sep;35(9):1143-52
14. Hammadani M, Kochuparambil ST, Osman S, Cumpston A, Leadmon S, Bunner P, Watkins K,
Morrison, D, Speir E, DeRemer D, Kota V, Jillella A, Craig M, Awan F. Intermediate –versus low
dose cyclophosphamide and granulocyte colony stimulating factor for peripheral blood stem cell
mobilization in multiple myeloma patients treated with novel induction therapies. Biol Blood
Marrow Transplant. 2012 Jul;18(7):1128-35
15. Awan F, Kochuparambil ST, DeRemer D, et al. Plerixafor salvage is safe and effective in
hard-to-mobilize patients undergoing chemotherapy and filgrastim-based peripheral blood
progenitor cell mobilization. J Oncol 2012;2012: 931071
16. Al-Husein B, Abdalla M, Trepte M, DeRemer DL, Somanath PR. Anti-angiogenic therapy for
cancer: An update. Pharmacotherapy. 2012 Dec;32(12):1095-111.
David L. DeRemer - CV
14
17. DeRemer DL, Katsanevas K, Bradley A, Awan F. Romiplostim resistance in secondary failure of
platelet recovery (SFPR). J Oncol Pharm Pract 2013 Dec;19(4):369-72
18. Bradley A, Devine M, DeRemer DL. Brentuximab vedotin: A novel antibody-drug conjugate. Am
J Health Syst Pharm. 2013 Apr 1;70(7):589-97
19. Awan F, Kochuparambil ST, Falconer DE, Cumpston A, Leadmon S, Watkins K, DeRemer D, Jillella
A, Craig M, Hamadani M. Comparable efficacy and lower cost of PBSC mobilization with
intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients
with multiple myeloma treated with novel therapies. Bone Marrow Transplant 2013
Oct;48(10):1279-84
20. Goc A, Al-Husein B, Katsanevas K, Steinbach A, Lou U, Sabbineni H, DeRemer DL, Somanath PR.
Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells
inhibit prostate cancer progression in vitro and in vivo. Oncotarget 2014 15;5(3):775-87.
21. Bradley A, Evans S, DeRemer DL, Awan F. Busulfan dosing (Q6 or Q24) with adjusted or actual
body weight, does it matter? J Oncol Pharm Pract. 2015 Dec;21(6):425-32.
22. Clark SM, Clemmons A, Schaack L, Garren J, DeRemer DL, Vota V. Fosaprepitant for the
prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before
autologous hematopoietic stem cell transplant. J Oncol Pharm Pract. 2016 Jun;22(3):416-22.
23. Hartranft M, Clemmons A, DeRemer DL, Kota V. Evaluation of romiplostim for the treatment of
secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant
patients. J Oncol Pharm Pract. J Oncol Pharm Pract. 2017 Jan;23(1):10-17
24. DeRemer DL, Clemmons AB, Orr J, Clark SM, Gandhi A. Emerging role of olanzapine for
prevention and treatment of chemotherapy-induced nausea and vomiting. Pharmacotherapy.
2016 Feb;36(2):218-29.
25. Mangonkar A, Xu H, Moshin J, Mansour J, Chintalapally R, Keen R, Mondal AK, DeRemer D, et al.
Prognostic value of complete remission with superior platelet counts in acute myeloid leukemia.
J Community Support Oncol. 2016 Feb;14(2):66-71.
26. Evans SS, Gandhi AS, Clemmons AB, DeRemer DL. Clinical and cost comparison evaluation of
inpatient versus outpatient administration of EPOCH‐Containing regimens in Non‐Hodgkin
lymphoma. J Pharm Pract. 2016 Jul 18. pii: 0897190016659210. [Epub ahead of print]
27. Deal EN, Stranges PM, Maxwell WD, Bacci J, Ashjian EJ, DeRemer DL, et al. The importance of
research and scholarly activity in pharmacy training. Pharmacotherapy. 2016 Dec;36(12):e200-
e205.
David L. DeRemer - CV
15
28. Andrick B, Alwahibi A, DeRemer DL, Quershi S, Khan R, Bryan L, Somanath PR, Pantin J. Lack of
adequate pneumococcal vaccination response in chronic lymphocytic leukemia patients
receiving ibrutinib. Br J Haematol. 2017 Jul 24 [epub ahead of print]
29. Gwynn ME, DeRemer DL. The emerging role of PD-1/PD-L1 targeting immunotherapy in the
treatment of metastatic urothelial carcinoma. Ann Pharmacother. 2017 Aug 1 [epub ahead of
print]
NON-PEERED REVIEWED
1. Adams VR, DeRemer, DL, Kilbridge JF. Apoptosis: Novel Molecular Targets in
Cancer Therapy, Clinical Focus on Bcl-2. Oncology Special Edition Dec 2004.
2. DeRemer DL. Blincyto® (blinatumomab) for patients with Philadelphia chromosome-negative
relapsed or refractory B-Cell precursor acute lymphoblastic leukemia. Submitted to Pharmacy
Practice News March 2015.
3. DeRemer DL. Empowering Community Pharmacists as Health Consultants: Chemotherapy-
Induced Nausea and Vomiting. Inside Patient Care. December 2015.
BOOK CHAPTERS
1. Gerson SL, Bhalla KN, Grant S, Natarajan K, Grant S, Creger RJ, DeRemer D. Pharmacology and
Molecular Mechanisms of Antineoplastics Agents for Hematologic Malignancies. In:
Hematology: Basic Principles and Practice (eds Hoffman R, Silberstein LE, Shattil SJ, et al.) 5th
edition. Elsevier, Philadelphia, PA. 2008, p 839-873.
2. DeRemer DL Leukemias. In: Sutton NAPLEX Review Guide. 1st edition. McGraw-Hill., New York.
2011 p143 -150.
3. DeRemer DL, Manasco KB, Fagan SC. Research: Becoming a Scholar. In: Murphy JE (ed)
American College of Clinical Pharmacy Resident Survival Guide. Lenexa, KS, 2011.
4. DeRemer DL. Drug and Food Interactions with Tyrosine Kinase Inhibitors. In: Ustun C and Popat
UR (eds): Chronic Myeloid Leukemia: From Daily Management to Complicated Issues. New York,
NY: Nova Science Publishers; 2014 pp. 251-262.
5. DeRemer DL Leukemias. In: Sutton NAPLEX Review Guide. 2nd edition. McGraw-Hill., New York.
2015.
6. DeRemer DL Leukemias. In: Sutton NAPLEX Review Guide. 3rd edition. McGraw-Hill., New York.
2017. (Submitted)
David L. DeRemer - CV
16
HANDBOOKS
1. Adams, V.R., DeRemer, DL, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens.
McMahon Publishing, New York, NY 2004
2. Adams, V.R., DeRemer, DL, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens.
McMahon Publishing, New York, NY 2005
3. Adams, V.R., DeRemer, DL, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens.
McMahon Publishing, New York, NY 2007
4. Adams, V.R., DeRemer, DL, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens.
McMahon Publishing, New York, NY 2008
5. Adams, V.R., DeRemer, DL, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens.
McMahon Publishing, New York, NY 2009
6. Adams, V.R., DeRemer, DL, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens.
McMahon Publishing, New York, NY 2010
7. Adams, V.R., DeRemer, DL, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens.
McMahon Publishing, New York, NY 2011
8. Adams, V.R., DeRemer, DL, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens.
McMahon Publishing, New York, NY 2012
9. Adams, V.R., DeRemer, DL, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens.
McMahon Publishing, New York, NY 2013
10. Adams, V.R., DeRemer, DL, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens.
McMahon Publishing, New York, NY 2014
11. Adams, V.R. DeRemer DL, Bernhardt, MB. Guide to Cancer Therapeutic Regimens. McMahon
Publishing, New York, NY 2017.
ABSTRACTS/POSTERS
1. Liewer SE, Hecht KA, Smith, CA, DeRemer DL, Adams VR, et al. Gelclair® for the treatment
chemotherapy induced stomatitis in transplant and hematology patients: An interim analysis.
Blood. 2004 Nov 16;104: 5317
David L. DeRemer - CV
17
2. Gallt RR, Mattingly CA, DeRemer DL, Adams VR. Determination of in vitro growth inhibition by
novel farnesyl diphosphate analogues. American College of Clinical Pharmacy (ACCP) Annual
Meeting 2005 San Francisco, CA. Abstract #511
3. DeRemer DL, Mattingly CA, Adams VR. In vitro interaction between topotecan (TPT) and
paclitaxel (PAC) in three human ovarian cancer cell lines. ACCP Annual Meeting 2005 San
Francisco, CA. Abstract #245
4. Kendrick A, Lake B, DeRemer D, Fain H, Farrow S, Ustun C, and Jillella A. Analysis of febrile
neutropenia in multiple myeloma patients post-autologous hematopoietic stem cell
transplantation (HSCT). Presented at the 2007 American Colleges of Clinical Pharmacy Annual
Meeting Denver, CO; October 15, 2007. Abstract #353.
5. Kendrick A, DeRemer DL. Evaluation of institutional BMT program compliance with
recommended post-hematopoietic stem cell transplant (HSCT) vaccination guidelines.
Presented at 2007 American Health System Pharmacy (ASHP) Annual Meeting Las Vegas, NV;
December 2007
6. Fussell J, Boyle K, Kuth J, DeRemer DL, Ustun C. Review of institutional use of prophylactic
voriconazole and posaconazole in patients with hematological malignancies. Presented at 2007
American Health System Pharmacy (ASHP) Annual Meeting Las Vegas, NV; December 2007.
7. Stevich B, Mattingly C, DeRemer DL, Spielmann P, Adams V. Targeting Ras with false prenyl
analogs. Presented at 2008 American Colleges of Clinical Pharmacy (ACCP) Annual Meeting
Louisville, KY; October 2008.
8. Carbonell C, DeRemer DL. Institutional analysis of rasburicase in the management of tumor lysis
syndrome. Presented at 2008 American Health System Pharmacy (ASHP) Annual Meeting
Orlando, FL. December 2008.
9. Nestor MA, DeRemer DL. Evaluation of outcomes in acute promyelocytic leukemia patients
receiving ATRA (All-trans Retinoic Acid). Presented at 2008 American Health System Pharmacy
(ASHP) Annual Meeting Orlando, FL. December 2008
10. Almeter PJ, Robinson T, DeRemer DL. Institutional evaluation of vancomycin in neutropenic
patients. Presented at 2008 American Health System Pharmacy (ASHP) Annual Meeting Orlando,
FL. December 2008.
11. Maciuleviciute E, Davis W, DeRemer DL. Evaluation of hypertension management bevacizumab
treated patients. Presented at the 2008 University Health Consortium Pharmacy Council
Resident Poster Session, Orlando, FL. December 6, 2008
David L. DeRemer - CV
18
12. Graham CR, Butterfield J, DeRemer DL. Impact of peptide nucleic acid fluorescence in situ
hybridization (PNA FISH)-based identification of Candida species on antifungal utilization.
Presented at the 2009 University Health Consortium Pharmacy Council Resident Poster Session,
Las Vegas, NV. December 5, 2009
13. Mebel E, McAllister J, DeRemer DL. Evaluation of plerixafor on stem cell collection prior to an
autologous hematopoietic stem cell transplant (aHSCT). Presented at 2009 American Health
System Pharmacy (ASHP) Annual Meeting Las Vegas, NV. December 2009.
14. Awan F, DeRemer D, Mebel E, et al. Utility of plerixafor in addition to chemotherapy and G-CSF
mobilization regimens. Blood (American Society of Hematology (ASH) Annual Meeting)
2010;116: 4443.
15. Katsanevas K, Ajiboye V, DeRemer DL. Evaluation of pegfilgrastim for primary prophylaxis for of
neutropenic fever. Presented at the 2010 University Health Consortium Pharmacy Council
Resident Poster Session, Anaheim, CA. December 4, 2010
16. Kochuparambil T, DeRemer DL, Mebel ER, Jillella AP, Awan F. Optimizing the efficacy of
plerixafor as a salvage option in poor mobilizers following chemotherapy plus G-CSF. Presented
at the 2011 American Society for Blood and Marrow Transplantation (ASBMT) Meeting.
Honolulu, HI. February 17-21, 2011
17. Stoudenmire LL, Trepte M, McCracken C, Katsanevas K, DeRemer DL. Evaluation of obesity on
achieving remission following induction therapy for acute myelogenous leukemia. ACCP Annual
Meeting 2011 Pittsburgh, PA. Abstract # 448
18. Morrison DD, Kochuparambil ST, DeRemer DL, et al. Clinical Practice Guideline for the treatment
of BK-Virus induced Hemorrhagic Cystitis in the Post-Allogeneic Hematopoietic Stem Cell
Transplant Setting. Volume 18 Issue 2. Presented at the American Society of Bone Marrow
Transplant (ASBMT) Annual Meeting at San Diego, CA. Feb 1-5, 2012.
19. Hamadani S, Kochuparambil ST, Osman S, Speir E, Craig M, DeRemer D, et al. Intermediate-
versus low-dose cyclophosphamide and granulocyte colony stimulating factor for peripheral
blood progenitor cell mobilization in patients with multiple myeloma treated with novel
induction chemotherapies – A multicenter analysis. Blood (ASH Annual Meeting Abstracts), Nov
2011;118: 313.
20. Katsanevas K, Al-Husein B, DeRemer D, Shenoy S. Is GSK-3 the gridlock in Akt-targeted prostate
cancer therapy? Presented at the 2012 Hematology/Oncology Pharmacist Association (HOPA)
Meeting, Orlando, FL. March 22, 2012.
David L. DeRemer - CV
19
21. DeRemer DL, Katsanevas K, Forehand C, et al. Successfully integrating translational research
into a PGY2 research project. Presented at the 2012 ASHP National Residency Preceptors
Conference in Washington, DC. August 17, 2012.
22. DeRemer DL, Katsanevas K, Lou U, et al. Src inhibition with dasatinib offers potential benefit for
prostate cancer. Presented at the 2012 STAR (Southern Translational Research) Conference in
Augusta, GA. September 6, 2012.
23. Evans S, DeRemer D, Bradley A. Intravenous busulfan pharmacokinetics in conditioning
regimens for allogeneic stem cell transplantation: impact of dosing weight on clinical outcomes.
Presented at the 2012 STAR (Southern Translational Research) Conference in Augusta, GA.
September 6, 2012.
24. Awan F, Kochuparambil ST, Craig M, Cumpstom A, Leadmon, S, Watkins K, DeRemer D, Pantin J,
Kota V, Jillella AP, Hamadani. Intermediate-Dose Cyclophosphamide Versus Plerixafor and
Granulocyte Colony Stimulating Factor (G-CSF) for Peripheral Blood Progenitor Cell (PBPC)
Mobilization in Patients with Multiple Myeloma (MM) Treated with Novel Induction
Chemotherapies – A Multicenter Analysis. Blood (ASH Annual Meeting Abstracts), Nov 2012;
120: 4409
25. Steinbach A, Goc A, DeRemer D, Shenoy S. Evaluation of cabazitaxel and dasatinib on the
reciprocity between prostate cancer and the endothelium in the prevention of micrometastasis.
Presented at the 9th Annual HOPA Conference in Los Angeles, GA. March 21, 2013.
26. Schaack L, Clark SM, Clemmons AB, DeRemer DL, Kota V. Characterization of chemotherapy
induced nausea and vomiting outcomes in patients receiving melphalan-containing conditioning
chemotherapy for autologous hematopoietic stem cell transplant. Presented at 2013 ACCP
Annual Meeting in Albuquerque, NM. Abs #347
27. Clark SM, Schaack L, DeRemer D, Kota V, Clemmons AB. Fosaprepitant for the prevention of
nausea and vomiting in patients receiving BEAM or high-dose melphalan conditioning regimens
for autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014
Feb;20(2 Suppl):S287.
28. Hartranft ME, DeRemer DL, Kolhe R, Phillips BG. Investigation of epigenetic modifications in
obese and non-obese acute myeloid leukemia patients. Presented at 10th Annual Meeting of the
Hematology/Oncology Pharmacy Association (HOPA), New Orleans, LA. Resident Trainee Poster
#125
29. DeRemer DL, Hartranft ME, Mondal A, Kolhe R, Meagher R, Phillips BG. Evaluation of the effects
of obesity on the epigenome in acute myeloid leukemia patients: Correlation with clinical
outcome and drug response. Presented at 2014 ACCP Annual Meeting in Austin, TX. Abs#442.
David L. DeRemer - CV
20
30. Evans S, Clemmons AB, Gandhi A, DeRemer D. Clinical and economic evaluation of inpatient
versus outpatient administration of EPOCH-containing regimens in Non-Hodgkin lymphoma.
Presented at 12th Annual Meeting of the Hematology/Oncology Pharmacy Association (HOPA),
Austin, TX. Resident Trainee Poster #32
31. Orr J, Clemmons AB, Gandhi A, DeRemer D. Randomized, placebo-controlled study of FOND
(fosaprepitant, ondansetron, dexamethasone) versus FOND+O (FOND plus olanzapine) for the
prevention of CINV in hematology patients receiving highly emetogenic chemotherapy regimens
(The FOND-O Study). Presented at 12th Annual Meeting of the Hematology/Oncology Pharmacy
Association (HOPA), Atlanta, GA. Resident Trainee Poster #100
32. Andrick B, DeRemer D, Abdul Sater- H, Bollag R, Pantin J, Shenoy S. Pneumococcal vaccine
response in chronic lymphocytic leukemia patients with ibrutinib. Presented at 12th Annual
Meeting of the Hematology/Oncology Pharmacy Association (HOPA), Atlanta, GA. Resident
Trainee Poster #27
33. Andrick B, Alwhaibi A, DeRemer D, Quershi, Khan R, Shenoy S, Pantin J. Antibody response to
pneumococcal conjugate vaccine (PCV13) in chronic lymphocytic leukemia patients receiving
ibrutinib. Blood 2016 128:5597.
34. George TJ, Starr JS, Parkeh HD, Ivery AM, Dang LH, Daily KC, Allegra CJ, DeRemer DL, et al. Final
toxicity results from a phase II study of 5-fluorouracil, oxaliplatin and dasatinib (FOLFOX-D) in
previously untreated metastatic pancreatic adenocarcinoma. Submitted to 2018 GU ASCO
Meeting.
GRANTS
1. Analysis of febrile neutropenia in multiple myeloma patients post-autologous hematopoietic
stem cell transplantation. University of Georgia Randy Ellison Cancer Research Grant. Project
period 10/06-5/07. (Primary Investigator, 50% effort). Total award $2000
2. Is GSK-3 the gridlock in Akt-targeted prostate cancer therapy? University of Georgia
Translational Research Initiative Grant. Project period 10/11-07/12. (Sub-Investigator, 5%
effort). Total award $7500
3. Evaluation of cabazitaxel and dasatinib on the reciprocity between prostate cancer and the
endothelium in the prevention of micrometastasis. Submitted 9/12 for University of Georgia
Translational Research Initiative Grant. Project period 10/12-07/13. (PI, 5% effort). Total award
$10,000
4. Examining TGFβ and Integrin αvβ3 Expression in Early and Aggressive Human Prostate and
Bladder Cancer Tissues as Biomarkers for early detection and as targets for therapy. Project
David L. DeRemer - CV
21
period 2013-14. University of Georgia Translational Research Initiative Grant. (Sub-investigator,
5% effort). Total award $10,000
5. Evaluation of the effects of obesity on the epigenome in acute myeloid leukemia patients:
Correlation with clinical outcome and drug response. University of Georgia College of Pharmacy
R.C. Wilson Fund. Project period 2014-2015. (PI, 75% effort). Total award $4,500
6. Pneumococcal vaccine response in chronic lymphocytic leukemia (CLL) patients receiving
ibrutinib. University of Georgia College of Pharmacy R.C. Wilson Fund. Project period 2015-
2016. (PI, 75% effort). Total award $4,000
CLINICAL TRIALS
1. A Phase IA/II, two-arm, multi-center, open-label, dose escalation study of LBH589 administered
orally via different dosing schedules in adult patients with advanced hematological
malignancies. – Role: Institutional Sub-I. 2006-2008.
2. A Phase I dose finding study of the anti-angiogenesis agent, AG-013736 in combinations of
paclitaxel/carboplatin, weekly paclitaxel, docetaxel, capecitabine, and gemcitabine/cisplatin in
patients with advanced solid tumors. - Role: Institutional Sub-I. 2007.
3. Randomized, placebo-controlled study of FOND (fosaprepitant, ondansetron, dexamethasone)
versus FOND+O (FOND plus olanzapine) for the prevention of chemotherapy induced nausea
and vomiting in hematology patients receiving highly emetogenic chemotherapy regimens: the
FOND-O Study. (NCT02635984)- Investigator Initiated Trial, Role: Institutional Sub-I. 2015-
current
4. An open-label study of rovalpituzumab tesirine in subjects with delta-like protein 3-expressing
advanced solid tumors. Role: Institutional Sub-I. 2017-current
5. A Phase I, open-label study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102
in patients with advanced solid tumors and varying degrees of renal impairment. Role:
Institutional Sub-I. 2017-current
6. A Phase 1/2, Open-label study of nivolumab monotherapy or nivolumab combined with
ipilimumab in subjects with advanced or metastatic solid tumors. Role: Institutional Sub-I. 2017-
current
7. A Phase 1 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the
safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of MEDI9447
alone and in combination with MEDI4736 in adult subjects with select advanced solid tumors.
Role: Institutional Sub-I. 2017-current
David L. DeRemer - CV
22
8. A Phase 1/2 study exploring the safety, tolerability, and efficacy of INCAGN01876 in combination
with immune therapies in subjects with advanced or metastatic malignancies. Role: Institutional
Sub-I. 2017 –current
OTHER SCHOLARLY/CREATIVE WORKS
1. In collaboration, developed – Required competency areas, goals, and objective for PGY2
Oncology Pharmacy Residencies (2017) - http://www.ashp.org/DocLibrary/Residents/Oncology-
Pharmacy-2016.pdf
HONORS AND AWARDS
2015 Elected to Fellowship in ACCP
2014 ACCP Annual Meeting – Best Paper Award
2014 ACCP Hematology/Oncology PRN FIT Program Scholarship Recipient
2012 Georgia Society of Health-System Pharmacists (GHSP) Outstanding
Practitioner of the Year
2005 ACCP Research Travel Award
2003 Clinical Pharmacy Residents Program Educational Grant- Pfizer
2003 University of Kentucky Medical Center Resident of the Month
1996 Howard Hughes Research Institute Research Award
ADMINISTRATIVE ACTIVITY/COMMITTEES
University of Florida Health Cancer Center
2017-present Member, Scientific Review and Monitoring Committee
2017-present Member, Data Integrity and Safety Committee
University of Georgia College of Pharmacy
2016-2017 Academic and Professionalism Committee
2013-2017 Student Wellness Committee
2013-2017 Students Oncological Advocates in Pharmacy (SOAP)- Faculty Advisor
David L. DeRemer - CV
23
2014-2016 Academic House Host – Augusta PGY3 students
2014-2016 Chair, Clinical Tracks Work Group
2010- 2012 UGA Faculty alternative delegate for American Association of Colleges
of Pharmacy (AACP)
2009-2013 Member, Scholarship and Awards Committee
2012-2013 Chair
2007-2009 Member, Faculty Development Committee
2006-2009 Admissions Committee
Augusta University (formerly known as -Georgia Regents University (GRU)
2012-2017 Member, Cancer Institutional Review Board (C-IRB)
2012-2017 Associate Member GRU Cancer Center
2008-2017 GRU/UGA Pharmacy Residency Advisory Committee (RAC) member
2006-2017 GRU BMT/Hematologic Malignancies Committee
2005-2017 GRU Oncology Pharmacy and Therapeutics Subcommittee
2005-2006 Medical College of Georgia (now GHSU) Palliative Care Committee
University of Kentucky
2003-2005 UK Oncology Pharmacy and Therapeutics Subcommittee
2003-2004 UK Medical Center Medication Use Evaluation Subcommittee
2002-2003 UK College of Pharmacy Admissions Committee (Resident member)
PROFESSIONAL ACTIVITY
2017- present American Society of Clinical Oncology (ASCO) member
2015-present National Community Oncology Dispensing Association (NCODA)
o Executive Advisory Board
2006-present Georgia Health Systems Pharmacy (GSHP) member
2006-present Hematology/Oncology Pharmacy Association (HOPA) member
o Vice-Chair, Tools and Resources Committee (2017)
o Board of Directors, Member at Large (2015- 2017)
Advocacy HOPA On the Hill Day Washington, DC 2015,
2016, 2017
Committee Restructuring Task Force 2016
Board Liaison, Practice Management (2016-2017)
Board Liaison, Annual Program Committee (2016-2017)
Board Liaison, Membership Committee (2015-2016)
Board Liaison, Publications Committee (2015- 2016)
BIG idea Taskforce (2015-current)
David L. DeRemer - CV
24
o Recognition Committee, Vice Chair (2014- current)
o Research and Abstract Review Committee (2010-2013)
o Poster Reviewer (2009-2012)
2002-present American College of Clinical Pharmacy (ACCP) Associate member
o Research Committee, member (2015-2016)
o Hematology/Oncology PRN Chair (2015-2016)
o Hematology/Oncology PRN Chair Elect (2014-2015)
o Hematology/Oncology PRN program committee (2014-current)
o Academy Resident Mentor participant (2013- current)
Mentee – Julianne Orr, Pharm.D. (PGY1 Resident,
Greenville Health System)
Mentee- Sarah Hayes, Pharm.D. (PGY1 Resident, N.
Memorial Medical Center)
Mentee- Deeter Neuman, Pharm.D. (PGY1 Resident,
University of Michigan)
Mentee – Manuel Cortez, Pharm.D. (PGY2 Oncology
Resident, University of Chicago)
o Student CV Reviewer (2012- current)
o Student Trivia Game Writer – Oncology (2010-2011) and (2016-
2017)
o Hematology/Oncology PRN Member (2003- current)
2012-2014 American Society for Blood and Marrow Transplantation – Affiliate
member
2005-2007 ASCO member
2002-2005 Kentucky Health System Pharmacists (KSHP) member
2001-present American Society of Health System Pharmacists (ASHP)
1998-2002 Kappa Psi Pharmaceutical Fraternity
CONSULTING
2013-2016 Merck – Speakers bureau
2010-2012 Georgia Department of Public Health - Georgia Cancer State Aid
Program Formulary Reviewer
SCIENTIFIC JOURNAL REFEREE AND BOOK REVIEWER
Books
Pharmacotherapy Principles and Practice -3rd edition
Chapter- Malignant Lymphomas
David L. DeRemer - CV
25
Journals
2017-present Supportive Care in Cancer
2017-present Journal of Pharmacy Technology
2016-present BMJ Open
2014-present Journal of Hematology/Oncology Pharmacy
2013-present Annals of Pharmacotherapy
2013-present Pharmacotherapy
2012-present American Journal of Health Systems Pharmacists
EDITORIAL ACTIVITY
Computer Apps for Oncology Professionals
2014- 2016 Essential oncology/McMahon Publishing
COMMUNITY SERVICE
2013-2017 Upward Sports Coach (Soccer, Basketball)
2009-2017 Leukemia and Lymphoma Society – Light the Night fundraising GRU
team member
2003-2005 Life Adventure Camp
1998-2002 Faith Pharmacy Volunteer
1992-1996 King of the Bluegrass Flag Football Tournament for Big Brothers/Big
Sisters